Related references
Note: Only part of the references are listed.Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology
Richard M. Goldberg et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities
Silvia Stacchiotti et al.
CANCER (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial
Anne-Sophie Defachelles et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Soft tissue sarcoma in adolescent and young adult patients: a retrospective study using a nationwide bone and soft tissue tumor registry in Japan
Takashi Fukushima et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)
A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma
Kazuhiro Tanaka et al.
BMC CANCER (2020)
Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation
Kazuhiro Tanaka et al.
SCIENTIFIC REPORTS (2020)
Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors
Andrea Ferrari et al.
EUROPEAN JOURNAL OF CANCER (2019)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis
Everardo D. Saad et al.
LANCET ONCOLOGY (2019)
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
Gianni Bisogno et al.
LANCET ONCOLOGY (2019)
A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses
Wanling Xie et al.
JNCI CANCER SPECTRUM (2019)
Fusion Status in Patients With Lymph Node-Positive (N1) Alveolar Rhabdomyosarcoma Is a Powerful Predictor of Prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
Soledad Gallego et al.
CANCER (2018)
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
Gianni Bisogno et al.
LANCET ONCOLOGY (2018)
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
Douglas S. Hawkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Differences in surrogate threshold effect estimates between original and simplified correlation-based validation approaches
Christoph Schuermann et al.
STATISTICS IN MEDICINE (2016)
Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting
Alona Zer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 Study
Odile Oberlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
D. Sargent et al.
EUROPEAN JOURNAL OF CANCER (2011)
Prognostic Factors After Relapse in Nonmetastatic Rhabdomyosarcoma: A Nomogram to Better Define Patients Who Can Be Salvaged With Further Therapy
Julia C. Chisholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparing Adult and Pediatric Rhabdomyosarcoma in the Surveillance, Epidemiology and End Results Program, 1973 to 2005: An Analysis of 2,600 Patients
Iyad Sultan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803
Carola A. S. Arndt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Does the Time-Point of Relapse Influence Outcome in Pediatric Rhabdomyosarcomas?
Adrian C. Mattke et al.
PEDIATRIC BLOOD & CANCER (2009)
Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma
S Mazzoleni et al.
CANCER (2005)
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer
A Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease
WM Crist et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group
PP Breitfeld et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2001)
Share Paper
